Tandem Diabetes Care touches one-year low after brokerages cut PTs

Tandem Diabetes Care

27/02/2025 15:54

Updates

** Shares of medical device maker Tandem Diabetes Care TNDM.O down 32% at $22.85, their lowest level in one year

** At least 3 brokerages cut PTs for the co, while maintaining "buy" or equivalent rating

** Co late on Wednesday forecast 2025 sales between $997 mln and $1.007 bln vs analysts' estimate of $1.004 billion - data compiled by LSEG

** TNDM also projected Q1 sales to be between $219 million and $224 million vs estimate of $220.3 million

** "What will likely cause investor consternation is the lower-than-anticipated Q1 2025 revenue guidance and the implied ramp through the rest of the year" - Brokerage Citi

** The 2025 outlook reflects the seasonal trends extending into Q1 - RBC Capital analysts

** TNDM has risen 16.4% in the last 12 months

 (Reporting by Siddhi Mahatole)

 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))